Mr Jason Aryeh is a life sciences investment fund manager and pharmaceutical industry expert with over twenty years of equity investment experience in the life sciences sector.
Mr. Aryeh is the Founder and managing General Partner of JALAA Equities, LP, a private hedge fund focused on the biotechnology and medical device sectors and has served in such capacity since 1997. He has also served as a member of the Board of Directors of Ligand Pharmaceuticals, Inc. (Nasdaq: LGND), a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines and has served as Ligand’s Chairman of its Nominating and Governance Committee since September 2006. As a shareholder-focused advocate, Mr. Aryeh has served on ten corporate or charitable foundation boards.
Eric S. Fain, M.D.
Dr. Eric S. Fain, M.D. is the former Senior Vice President and Group President, Cardiovascular and Neuromodulation at Abbott following its acquisition of St. Jude Medical.
Dr. Fain became Group President of St. Jude Medical in 2014 where he was responsible for global sales, marketing and clinical affairs across the entire St. Jude Medical portfolio worldwide.
Dr. Fain joined St. Jude Medical in 1997 as Vice President, Systems Development as part of the company’s acquisition of Ventritex, Inc., where he had worked since 1987. He went on to become Senior Vice President, Clinical/Regulatory Affairs for the St. Jude Medical Cardiac Rhythm Management Division (CRMD) in 1998. He was later promoted to Executive Vice President, Development and Clinical/Regulatory Affairs for CRMD in 2005 and then President of CRMD in 2007. Prior to his role as Group President, Dr. Fain was President of the company’s Implantable Electronic Systems Division beginning in 2012 when its CRM and Neuromodulation Divisions merged. Dr. Fain received his M.D. from Stanford University School of Medicine and holds a Sc.B. degree in applied math/biology from Brown University.
John R. Barr
Mr. John R. Barr has spent his career in medical devices. From October 2014 until August 2017, Mr. Barr has served as CEO at Surgical Specialties Inc., a privately held medical device firm specializing in wound closure and surgical knives that was sold to an investor group in March 2017.
Prior to that, he served as Executive Vice President and President of Global Surgical at Bausch & Lomb Holdings Incorporated until its acquisition by Valeant Pharmaceuticals in August 2013. Prior to Bausch and Lomb, Mr. Barr was the Chief Executive Officer of AGA Medical Holdings, a pioneer and leader in the development, sale and manufacture of disposable devices used in minimally invasive repair of structural heart defects and other vascular defects. Mr. Barr led an initial public offering for the Company in 2009 and the business was sold to St. Jude Medical in 2010.
Mr. Barr served as CEO of V.I. Technologies from and led its initial public offering in 1998. The mission of V.I. Technologies was to commercialize pathogen inactivation technology for transfusion blood products. Prior to V.I. Technologies he served as President of North American Operations and a member of the Board at Haemonetics Corp., where he had responsibility for Haemonetics’ blood bank, commercial plasma and blood bank services businesses. From July 1981 to April 1990, Mr. Barr held various positions at Baxter Healthcare Corp.
Mr. Barr is currently a member of the Board of EarlySense, LLC, a pioneer in the development of contactless monitoring for use in acute, sub-acute and home settings. Mr. Barr is a graduate of the J.L. Kellogg Graduate School of Management-Northwestern University where he earned his master’s degree in finance, accounting and economics. He earned his undergraduate degree in bioengineering from the University of Pennsylvania.
Eric A. Rose, M.D.
Dr. Eric Rose is a world-renowned innovative surgeon and scientist, best known for making history in 1984 when he performed the landmark achievement of the first successful pediatric heart transplant.
Over the course of his career, he has continued to study and improve cardiac surgical care in children and adults. He currently serves as the Executive Chairman of the Board of Directors of SIGA Technologies, Inc. (Nasdaq: SIGA), a commercial-stage pharmaceutical company focused on serious unmet medical needs and biothreats. Previously, he had served as Chairman and CEO of SIGA. Dr. Rose chaired the Department of Health Evidence & Policy at the Mount Sinai School of Medicine from 2008 to 2012. From 1994 through 2007, he served as Chairman of the Department of Surgery and Surgeon-in-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital. In addition to his roles at SIGA, Dr. Rose holds a position as Executive Vice President – Life Sciences at MacAndrews & Forbes Incorporated, the holding company of Ronald O. Perelman and a related party to SIGA. In 2010, Dr. Rose became a director of Abiomed, Inc. (Nasdaq: ABMD), a leading provider of medical devices that provide circulatory support. In April 2013, he became a director for Mesoblast Inc. (Nasdaq: MESO), an advanced cellular medicine company, where he serves as Chairman of the Scientific and Technology Committee. Over the course of his career, Dr. Rose has authored or co-authored more than 300 peer-reviewed publications on topics such as cardiovascular surgery, ventricular assist devices, and cardiac transplantation, and he is the author of two books: Management of End-Stage Heart Disease and Second Opinion: The Columbia Presbyterian Guide to Surgery. Throughout his career, he has been involved in grants totaling more than $25 million in funding, including, a large National Heart, Lung, and Blood Institute project, the Human Biology of Long-Term Mechanical Circulatory Support.
Mr. Gary Pruden is a proven industry leader with a broad background in technology and pharmaceutical innovation and M&A transactions.
Over the course of his 32-year career at Johnson and Johnson (NYSE: JNJ), Mr. Pruden held numerous senior leadership positions across both the medical devices and pharmaceutical sectors. As the Worldwide Chairman of the Medical Device group, he led a global business where new technologies, global expansion and focus on the patient were keys to success. He currently serves as a member of the Board of Directors of Motus GI Holdings, Inc. (Nasdaq: MOTS), an Orchestra-founded company. During his career at J&J, Mr. Pruden led a large global business with a significant portion of sales coming from outside of the United States including a strong focus on emerging markets. During his time at J&J, Mr. Pruden also helped lead the strategic collaboration with Google that was established for the advancement of surgical robotics. He has extensive experience in portfolio management including two large divestitures (Cordis Corporation and Codman Neurosurgery) and exits of non-strategic businesses, quality and compliance, as well as global regulatory experience. Additionally, Mr. Pruden serves as an Independent Director of Lantheus Holdings, Inc. (Nasdaq: LNTH).
David Pacitti is President of Siemens Medical Solutions, Inc. and Head of Siemens Healthineers North America.
Based at the U.S. headquarters of Siemens Healthcare in Malvern, Pennsylvania, Mr. Pacitti is responsible for leading the marketing, sales, service, and support functions in the U.S., with additional oversight of Canada, across the entire Healthcare portfolio, including medical imaging, laboratory diagnostics, therapy solutions, and services.
Prior to joining Siemens in 2015 in his current role, Mr. Pacitti was Division Vice President of U.S. Commercial Operations, Sales, and Marketing at Abbott Vascular for two years, overseeing the company’s business in North America. As a member of the Senior Executive Staff, he worked with the CEO, CFO, and Research & Development team on business development initiatives and played pivotal roles in key launches, including Abbott Vascular’s first drug-eluting stent franchise and structural heart franchise. Prior to this position, Mr. Pacitti was Vice President of Abbott Vascular’s Commercial Operations from 2009 to 2013, and Vice President of Global Marketing from 2006 to 2009. He joined Abbott Vascular with its acquisition of Guidant Corp, where he served in positions of increasing responsibility from 1995 to 2006. Early in Mr. Pacitti’s career, he was a sales representative in Siemens’ Molecular Imaging business.
A Philadelphia area native, Pacitti holds a Bachelor of Arts degree in Economics with a minor in Science from Villanova University, where his football prowess earned him induction into the Villanova Varsity Club Hall of Fame in 2006. Following college, in 1990 he signed a free agent contract with the Miami Dolphins as an Offensive Lineman.
Mr. Louis Shapiro is President and CEO of Hospital for Special Surgery (“HSS”). He has served in this role since October 2006, overseeing all strategic and operational aspects of HSS and fulfilling its mission to advance the field of musculoskeletal medicine through world-class patient care, research and education.
Under Mr. Shapiro’s leadership, HSS has experienced significant growth, expansion of facilities and recognition as the world leader in its specialty areas of orthopedics, rheumatology and their related disciplines. His hands-on leadership has led to extremely high employee engagement. HSS has received the prestigious Gallup Great Workplace Award twice for the most engaged workplaces in the world.
Mr. Shapiro has more than 30 years of healthcare experience, including as Executive Vice President and Chief Operating Officer of Geisinger Health System in Pennsylvania, and as a leader in the healthcare practice at McKinsey & Company. He began his career at Allegheny General Hospital in Pittsburgh, where he served in a number of capacities. In the past, Mr. Shapiro has served as Board Chairman of the Greater New York Hospital Association, for which he continues to serve on the Executive Committee and others. He also serves on the Board of Crutches for Kids, Move Mountains Foundation and Prep for Prep. Mr. Shapiro earned his BS and MHA degrees from the University of Pittsburgh.